127 related articles for article (PubMed ID: 14620141)
1. Anti-complement strategies in experimental sepsis.
Ward PA; Riedemann NC; Guo RF; Huber-Lang M; Sarma JV; Zetoune FS
Scand J Infect Dis; 2003; 35(9):601-3. PubMed ID: 14620141
[TBL] [Abstract][Full Text] [Related]
2. Role of C5a-C5aR interaction in sepsis.
Guo RF; Riedemann NC; Ward PA
Shock; 2004 Jan; 21(1):1-7. PubMed ID: 14676676
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a functional role of the second C5a receptor C5L2.
Gao H; Neff TA; Guo RF; Speyer CL; Sarma JV; Tomlins S; Man Y; Riedemann NC; Hoesel LM; Younkin E; Zetoune FS; Ward PA
FASEB J; 2005 Jun; 19(8):1003-5. PubMed ID: 15784721
[TBL] [Abstract][Full Text] [Related]
4. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis.
Riedemann NC; Guo RF; Hollmann TJ; Gao H; Neff TA; Reuben JS; Speyer CL; Sarma JV; Wetsel RA; Zetoune FS; Ward PA
FASEB J; 2004 Feb; 18(2):370-2. PubMed ID: 14688199
[TBL] [Abstract][Full Text] [Related]
5. C5a receptor and thymocyte apoptosis in sepsis.
Riedemann NC; Guo RF; Laudes IJ; Keller K; Sarma VJ; Padgaonkar V; Zetoune FS; Ward PA
FASEB J; 2002 Jun; 16(8):887-8. PubMed ID: 12039868
[TBL] [Abstract][Full Text] [Related]
6. A key role of C5a/C5aR activation for the development of sepsis.
Riedemann NC; Guo RF; Ward PA
J Leukoc Biol; 2003 Dec; 74(6):966-70. PubMed ID: 12960283
[TBL] [Abstract][Full Text] [Related]
7. C5a, a therapeutic target in sepsis.
Guo RF; Ward PA
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):57-65. PubMed ID: 18221134
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil C5a receptor and the outcome in a rat model of sepsis.
Guo RF; Riedemann NC; Bernacki KD; Sarma VJ; Laudes IJ; Reuben JS; Younkin EM; Neff TA; Paulauskis JD; Zetoune FS; Ward PA
FASEB J; 2003 Oct; 17(13):1889-91. PubMed ID: 12897064
[TBL] [Abstract][Full Text] [Related]
9. Protection of innate immunity by C5aR antagonist in septic mice.
Huber-Lang MS; Riedeman NC; Sarma JV; Younkin EM; McGuire SR; Laudes IJ; Lu KT; Guo RF; Neff TA; Padgaonkar VA; Lambris JD; Spruce L; Mastellos D; Zetoune FS; Ward PA
FASEB J; 2002 Oct; 16(12):1567-74. PubMed ID: 12374779
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of C5a blockade in sepsis.
Czermak BJ; Sarma V; Pierson CL; Warner RL; Huber-Lang M; Bless NM; Schmal H; Friedl HP; Ward PA
Nat Med; 1999 Jul; 5(7):788-92. PubMed ID: 10395324
[TBL] [Abstract][Full Text] [Related]
11. The role of C5a in the innate immune response after experimental blunt chest trauma.
Flierl MA; Perl M; Rittirsch D; Bartl C; Schreiber H; Fleig V; Schlaf G; Liener U; Brueckner UB; Gebhard F; Huber-Lang MS
Shock; 2008 Jan; 29(1):25-31. PubMed ID: 17621257
[TBL] [Abstract][Full Text] [Related]
12. The harmful role of c5a on innate immunity in sepsis.
Ward PA
J Innate Immun; 2010; 2(5):439-45. PubMed ID: 20588003
[TBL] [Abstract][Full Text] [Related]
13. Increased C5a receptor expression in sepsis.
Riedemann NC; Guo RF; Neff TA; Laudes IJ; Keller KA; Sarma VJ; Markiewski MM; Mastellos D; Strey CW; Pierson CL; Lambris JD; Zetoune FS; Ward PA
J Clin Invest; 2002 Jul; 110(1):101-8. PubMed ID: 12093893
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.
Riedemann NC; Neff TA; Guo RF; Bernacki KD; Laudes IJ; Sarma JV; Lambris JD; Ward PA
J Immunol; 2003 Jan; 170(1):503-7. PubMed ID: 12496437
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of anti-C5a peptide antibodies in experimental sepsis.
Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Guo RF; Padgaonkar VA; Younkin EM; Laudes IJ; Riedemann NC; Younger JG; Ward PA
FASEB J; 2001 Mar; 15(3):568-70. PubMed ID: 11259369
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.
Guo RF; Huber-Lang M; Wang X; Sarma V; Padgaonkar VA; Craig RA; Riedemann NC; McClintock SD; Hlaing T; Shi MM; Ward PA
J Clin Invest; 2000 Nov; 106(10):1271-80. PubMed ID: 11086028
[TBL] [Abstract][Full Text] [Related]
17. Regulation of IL-8 production by complement-activated product, C5a, in vitro and in vivo during sepsis.
Wang L; Han G; Wang R; Chen G; Xu R; Xiao H; Li X; Geng S; Li Y; Li X; Wang J; Feng J; Riedemann NC; Guo R; Shen B; Li Y
Clin Immunol; 2010 Oct; 137(1):157-65. PubMed ID: 20591742
[TBL] [Abstract][Full Text] [Related]
18. Role of C5a in multiorgan failure during sepsis.
Huber-Lang M; Sarma VJ; Lu KT; McGuire SR; Padgaonkar VA; Guo RF; Younkin EM; Kunkel RG; Ding J; Erickson R; Curnutte JT; Ward PA
J Immunol; 2001 Jan; 166(2):1193-9. PubMed ID: 11145701
[TBL] [Abstract][Full Text] [Related]
19. Role of the complement in experimental sepsis.
Ward PA
J Leukoc Biol; 2008 Mar; 83(3):467-70. PubMed ID: 17875813
[TBL] [Abstract][Full Text] [Related]
20. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction.
Niederbichler AD; Hoesel LM; Westfall MV; Gao H; Ipaktchi KR; Sun L; Zetoune FS; Su GL; Arbabi S; Sarma JV; Wang SC; Hemmila MR; Ward PA
J Exp Med; 2006 Jan; 203(1):53-61. PubMed ID: 16380509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
